Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Lancet
    February 2026
  1. GROARKE EM, Turturice B, Patel BA, Quinn KA, et al
    VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
    Lancet. 2026;407:637-648.
    >> Share

    January 2026
  2. ABIZAID A, Mehran R, Oliva A, Chamie D, et al
    Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
    Lancet. 2026 Jan 8:S0140-6736(25)02157-9. doi: 10.1016/S0140-6736(25)02157.
    >> Share

    November 2025
  3. FISHER BA
    Nipocalimab for Sjogren's disease-the importance of autoantibodies.
    Lancet. 2025;406:2397-2398.
    >> Share

  4. GAO J, Li M, Sun M, Yu Y, et al
    Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.
    Lancet. 2025 Nov 12:S0140-6736(25)01671-X. doi: 10.1016/S0140-6736(25)01671.
    >> Share

  5. ZIEGLER AG, Achenbach P, Weiss A, Berner R, et al
    Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
    Lancet. 2025 Nov 11:S0140-6736(25)01726-X. doi: 10.1016/S0140-6736(25)01726.
    >> Share

    October 2025
  6. CACOUB P, Vieira M, Langford CA, Tazi Mezalek Z, et al
    Large-vessel vasculitis.
    Lancet. 2025;406:2017-2032.
    >> Share

  7. FILIPPI M, Rocca MA
    MS-STAT2: lessons from negative trials in multiple sclerosis.
    Lancet. 2025 Oct 1:S0140-6736(25)01673-3. doi: 10.1016/S0140-6736(25)01673.
    >> Share

  8. CHATAWAY J, Williams T, Blackstone J, John N, et al
    Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Oct 1:S0140-6736(25)01039-6. doi: 10.1016/S0140-6736(25)01039.
    >> Share

    September 2025
  9. ZIEGLER AG, Cengiz E, Kay TWH
    The future of type 1 diabetes therapy.
    Lancet. 2025 Sep 19:S0140-6736(25)01438-2. doi: 10.1016/S0140-6736(25)01438.
    >> Share

  10. MATHIEU C, Wych J, Hendriks AEJ, Van Ryckeghem L, et al
    Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
    Lancet. 2025 Sep 18:S0140-6736(25)01674-5. doi: 10.1016/S0140-6736(25)01674.
    >> Share

    March 2025
  11. BANERJEE SS, Sahai S, Chate GP
    Guillain-Barre syndrome outbreak in Pune: a health emergency.
    Lancet. 2025 Mar 21:S0140-6736(25)00414-3. doi: 10.1016/S0140-6736(25)00414.
    >> Share

  12. LATEEF S
    India faces major Guillain-Barre syndrome epidemic.
    Lancet. 2025;405:769.
    >> Share

    January 2025
  13. ACHARYA NR, Ramanan AV, Coyne AB, Dudum KL, et al
    Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
    Lancet. 2025;405:303-313.
    >> Share

  14. BENHADOU F, Cogan E
    Targeting IFNbeta in dermatomyositis.
    Lancet. 2025;405:99-101.
    >> Share

  15. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
    Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2025;405:137-146.
    >> Share

    November 2024
  16. DE FREMONT GM, Lenfant T, Le Guern V, Costedoat-Chalumeau N, et al
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2163.
    >> Share

  17. MATUCHANSKY C
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2163.
    >> Share

  18. HOI A, Igel T, Mok CC, Arnaud L, et al
    Therapies for systemic lupus erythematosus - Authors' reply.
    Lancet. 2024;404:2163-2164.
    >> Share

  19. XU Q
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2162.
    >> Share

  20. PABST T, Maurer B
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2162.
    >> Share

  21. HAGEN M, Muller F, Wirsching A, Kharboutli S, et al
    Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells.
    Lancet. 2024;404:2158-2160.
    >> Share

    September 2024
  22. LOVE KM, Brown SA
    The promise of once-weekly insulins for type 1 diabetes: update on progress.
    Lancet. 2024;404:1081-1083.
    >> Share

  23. BERGENSTAL RM, Weinstock RS, Mathieu C, Onishi Y, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
    Lancet. 2024;404:1132-1142.
    >> Share

    August 2024
  24. AL-SAMKARI H, B Bussel J, Miyakawa Y, Broome CM, et al
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.
    Lancet. 2024;404:434.
    >> Share

  25. JACOBS JW, Booth GS, Stephens LD, Tormey CA, et al
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
    Lancet. 2024;404:433.
    >> Share

  26. MA RW, Liu K, Xie J
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
    Lancet. 2024;404:433-434.
    >> Share

    July 2024
  27. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell perspectives in lupus - Authors' reply.
    Lancet. 2024;404:336-337.
    >> Share

  28. GREMESE E, Bruno D, Ferraccioli G
    CAR T-cell perspectives in lupus.
    Lancet. 2024;404:336.
    >> Share

    June 2024
  29. LAFAYETTE R, Kristensen J, Stone A, Barratt J, et al
    Targeted release of budesonide in primary IgA nephropathy - Authors' reply.
    Lancet. 2024;403:2786.
    >> Share

  30. ZOU Y, Du X, Zou J
    Targeted release of budesonide in primary IgA nephropathy.
    Lancet. 2024;403:2785-2786.
    >> Share

  31. HU Y, Zhang Y
    Targeted release of budesonide in primary IgA nephropathy.
    Lancet. 2024;403:2785.
    >> Share

  32. SAKUMA I, Ishibashi R, Matsue K, Vatner DF, et al
    Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man.
    Lancet. 2024;403:e33.
    >> Share

    April 2024
  33. HOI A, Igel T, Mok CC, Arnaud L, et al
    Systemic lupus erythematosus.
    Lancet. 2024 Apr 17:S0140-6736(24)00398-2. doi: 10.1016/S0140-6736(24)00398.
    >> Share

  34. KRICKAU T, Naumann-Bartsch N, Aigner M, Kharboutli S, et al
    CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis.
    Lancet. 2024 Apr 17:S0140-6736(24)00424-0. doi: 10.1016/S0140-6736(24)00424.
    >> Share

    February 2024
  35. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    >> Share

  36. VAN DER HELM-VAN MIL AHM
    Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
    Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
    >> Share

    January 2024
  37. WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al
    Complement in human disease: approved and up-and-coming therapeutics.
    Lancet. 2024;403:392-405.
    >> Share

  38. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    >> Share

    November 2023
  39. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
    Multiple sclerosis.
    Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
    >> Share

  40. REICH HN, Barbour SJ
    PROTECTing the kidneys in IgA nephropathy.
    Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418.
    >> Share

  41. ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al
    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302.
    >> Share

  42. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    >> Share

    October 2023
  43. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    >> Share

  44. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    >> Share

  45. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    >> Share

    September 2023
  46. BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al
    Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460.
    >> Share

  47. MAHAMAD S, Arnold DM
    Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
    Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836.
    >> Share

  48. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016